Dr. Arend, an assistant professor and senior scientist at the University of Alabama at Birmingham has received funding from 2 drug companies – Bristol Meyers Squib and Exelixis to perform an investigator initiated trial for patients with carcinosarcoma: “A phase II single arm study of cabozantinib plus nivolumab in women with recurrent gynelocological